Cargando…
A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
Pancreatic neuroendocrine tumor (PanNET) is a neoplastic entity in which few prognostic factors are well-known. Here, we aimed to evaluate the prognostic significance of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain famil...
Autores principales: | Viúdez, Antonio, Carvalho, Filipe L.F., Maleki, Zahra, Zahurak, Marianna, Laheru, Daniel, Stark, Alejandro, Azad, Nilofer Z., Wolfgang, Christopher L., Baylin, Stephen, Herman, James G., De Jesus-Acosta, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041882/ https://www.ncbi.nlm.nih.gov/pubmed/26894863 http://dx.doi.org/10.18632/oncotarget.7436 |
Ejemplares similares
-
Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
por: Viúdez, Antonio, et al.
Publicado: (2017) -
Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
por: Megdanova-Chipeva, Vera G., et al.
Publicado: (2020) -
Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?
por: Marinoni, Ilaria
Publicado: (2022) -
A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective
por: Werle, Silke D., et al.
Publicado: (2023) -
Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
por: Ramage, John K., et al.
Publicado: (2022)